Menu
Recruiting NCT04461444

COhort for Bardet-Bield Syndrome and Alström Syndrome for Translational Research Monocentric Interventional Study

No phase Interventional Bardet-Biedl Syndrome Alström Syndrome

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Skin biopsy.
Who it may be relevant to
Registry conditions: Bardet-Biedl Syndrome, Alström Syndrome. Basic parameters: from 4 months · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
France
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

COhort for Bardet-Bield Syndrome and Alström Syndrome for Translational Research Etude Interventionnelle Monocentrique

Overview

ALMS and BBS syndromes are rare diseases with overlapping features of multiple sensory and metabolic impairments, including diabetes mellitus. There are to date no specific treatments available and limited information on the natural history of the diseases. the investigators aim to establish a French cohort for these diseases to improve patient care and assess the effect of actual therapies on quality of life. The purpose of this study is to establish a cohort of Bardet-Bield syndrome (BBS) and ALström syndrome (ALMS) patients in order to formalize and address questions concerning the in-depth natural clinical and biological history of the disease on the long term for a given patient, establish the impact on the quality of life of various clinical manifestations

Interventions

  • Genetic Skin biopsy
    COBBALT is considered as an interventional with minor associated risks and constrains study due to the presence of skin biopsies that may not all be part of the usual medical practice. Risks are those linked to the biopsy procedure: * risk of pain due to the procedure performed under local anaesthesia * can leave a visible scar (about 2 x 1 cm)

Primary outcome measures

  • Clinical history description of Bardet-Biedl (BBS) and ALström syndromes (ALMS). [Time frame: 5 years]
  • Clinical history description of Bardet-Biedl (BBS) and ALström syndromes (ALMS). [Time frame: 5 years]
  • Clinical history description of Bardet-Biedl (BBS) and ALström syndromes (ALMS). [Time frame: 5 years]
  • Clinical history description of Bardet-Biedl (BBS) and ALström syndromes (ALMS). [Time frame: 5 years]

Eligibility criteria

Inclusion criteria

  • Patients of both sex
  • Age minimum\*
  • patients with social protection
  • Written informed consent form signed prior initiating any trial related procedure:
  • by > 18-year old patients
  • by both parents for minor patients > 4 months or legal representative for protected adults, and by minor and protected adults patients if able to understand and/or give their assent.
  • For foreign patients, a third party will translate, if required, the information prior to the consent.
  • a diagnosis of BBS or ALMS based on molecular assessment or clinical evaluation/or patient with mutation and none of the diagnosis criteria
  • and/or an identified mutation in BBS genes or ALMS1 gene
  • The inclusion of children is essential to a cohort study that is attempting an early identification of visual, metabolic and renal abnormalities. Many of the age-dependent manifestations of BBS develop during childhood and the average age of diagnosis is 9.2 years

Exclusion criteria

  • Serious active intercurrent pathology that may impact the collected data
  • Patient under judicial protection
  • Participation in another interventional clinical trial which includes an exclusion period
  • Non protected adult with difficulty of comprehension, or inability to understand the delivered information (emergency situation ...).

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Supportive care

Study locations

France · 1 center
  • Les Hôpitaux Universitaires de Strasbourg — Strasbourg

Identifiers

NCT: NCT04461444 · 7076

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗